Heron療法 HRTX 深 滬
已收盤 05-08 16:00:00 美东时间
1.21
-0.030
-2.42%
華盛通- 最 高1.25
- 今 開1.25
- 成交量 179.46万股
- 最 低 1.205
- 昨 收 1.24
- 總市值 2.28亿
- 52周最高 2.30
- 市盈率 靜 --
- 換手率 0.95%
- 52周最低 0.7362
- 委 比 44.20%
- 總股本 1.89亿
- 歷史最高 42.90
- 量 比 0.72
- 振 幅 3.63%
- 歷史最低 0.16
- 每 手 1
- 風險率 0.39%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多新浪财经ESG：Heron Therapeutics Inc. MSCI（明晟）ESG评级调升至BB
新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务，助力上市公司传播ESG理念，提升ESG可持续发展表现。点击查看【 ESG评级中...
03-24 10:22
期权扫描 | 绩前踏入“5000亿美元俱乐部”，美光获一Call单押注续升至500美元；SoFi期权成交活跃，连续两日登榜TOP10
绩前踏入“5000亿美元俱乐部”，美光获一Call单押注续升至500美元；遭浑水做空！SoFi期权成交活跃，连续两日登榜TOP10；微软看跌期权连日攀升至超六成>>
03-18 19:20
Heron Therapeutics shares are trading higher after the company reported better-than-expected Q4 sales results and issued FY26 sale guidance above estimates.
Heron Therapeutics shares are trading higher after the company reported better-...
02-27 01:34
Earnings Scheduled For February 26, 2026
Companies Reporting Before The Bell • Enovis (NYSE:ENOV) is estimated to report...
02-26 19:11
Heron Therapeutics Inc. to Report Q4 and Full Year 2025 Results
Heron Therapeutics Inc. to Report Q4 and Full Year 2025 Results Heron Therapeutics Inc. will report its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. The company will host a conference call and live webcast at 8:30 a.m. ET to discuss the results and recent busin
02-17 21:30
美股大行评级 | 瑞穗上调英伟达、谷歌、美光科技、SanDisk多家科技股目标价；中金首予诺和诺德"跑赢大市"评级，目标价73.5美元
今日重点评级关注：Needham：维持Cartesian Therapeutics"买入"评级，目标价从40美元升至42美元；Piper Sandler：维持Acrivon Therapeutics"超配"评级，目标价从6美元升至8美元
01-12 14:09
HC Wainwright & Co. Reiterates Buy on Heron Therapeutics, Maintains $6 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Heron Therapeutics (NASDAQ:HRTX) with a Buy and maintains $6 price target.
01-10 00:35
Heron Therapeutics Reports Q4 Preliminary Net Revenue Of ~$40.5M, ~$154.9M For 2025
Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced preliminary, unaudited fourth quarter and full-year 2025 net revenue.Net revenue of
01-09 22:31
Heron Therapeutics Includes APONVIE Injectable Emulsion In Guidelines For Postoperative Nausea, Vomiting
Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the inclusion of APONVIE® (aprepitant) injectable emulsion in the newly released Fifth
2025-12-04 21:17
BRIEF-Heron Therapeutics Announces Inclusion Of Aponvie (Aprepitant)
Dec 4 (Reuters) - Heron Therapeutics Inc HRTX.O: HERON THERAPEUTICS ANNOUNCES INCLUSION OF APONVIE® (APREPITANT) INJECTABLE EMULSION IN THE NEWLY RELEASED FIFTH CONSENSUS GUIDELINES FOR THE MANAGEMENT...
2025-12-04 21:17
